Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 37799 | 31.515 |
09:33 ET | 15039 | 31.63 |
09:35 ET | 12299 | 31.42 |
09:37 ET | 13728 | 31.71 |
09:39 ET | 16237 | 31.835 |
09:42 ET | 16677 | 32.03 |
09:44 ET | 18425 | 32.2 |
09:46 ET | 17142 | 32.3 |
09:48 ET | 15931 | 32.46 |
09:50 ET | 69068 | 32.823138 |
09:51 ET | 33544 | 32.96 |
09:53 ET | 18766 | 32.78 |
09:55 ET | 17889 | 32.6 |
09:57 ET | 47814 | 32.65 |
10:00 ET | 23827 | 32.63 |
10:02 ET | 8451 | 32.61 |
10:04 ET | 15377 | 32.415 |
10:06 ET | 18420 | 32.435 |
10:08 ET | 5339 | 32.275 |
10:09 ET | 10779 | 32.39 |
10:11 ET | 8218 | 32.38 |
10:13 ET | 6202 | 32.615 |
10:15 ET | 76423 | 32.79 |
10:18 ET | 27112 | 33.16 |
10:20 ET | 12596 | 33.31 |
10:22 ET | 21437 | 33.46 |
10:24 ET | 9046 | 33.39 |
10:26 ET | 12729 | 33.21 |
10:27 ET | 18499 | 33.07 |
10:29 ET | 4971 | 33.06 |
10:31 ET | 7984 | 33.045 |
10:33 ET | 5162 | 33.055 |
10:36 ET | 20086 | 33.2 |
10:38 ET | 7178 | 33.335 |
10:40 ET | 6745 | 33.28 |
10:42 ET | 8313 | 33.205 |
10:44 ET | 9637 | 33.34 |
10:45 ET | 18398 | 33.39 |
10:47 ET | 6154 | 33.48 |
10:49 ET | 38159 | 33.5429 |
10:51 ET | 26598 | 33.595 |
10:54 ET | 32570 | 33.53 |
10:56 ET | 13691 | 33.7 |
10:58 ET | 26282 | 33.78 |
11:00 ET | 17577 | 33.94 |
11:02 ET | 28613 | 34.02 |
11:03 ET | 16090 | 33.95 |
11:05 ET | 5023 | 34 |
11:07 ET | 28132 | 33.66 |
11:09 ET | 17062 | 33.6383 |
11:12 ET | 11925 | 33.57 |
11:14 ET | 13160 | 33.8 |
11:16 ET | 8975 | 33.98 |
11:18 ET | 19514 | 34.09 |
11:20 ET | 70572 | 34.13 |
11:21 ET | 22045 | 34.07 |
11:23 ET | 29630 | 33.925 |
11:25 ET | 11875 | 34.033854 |
11:27 ET | 17350 | 33.8822 |
11:30 ET | 11652 | 33.91 |
11:32 ET | 5408 | 33.845 |
11:34 ET | 24385 | 33.91 |
11:36 ET | 123323 | 34.0576 |
11:38 ET | 80516 | 34.39 |
11:39 ET | 18585 | 34.435 |
11:41 ET | 46421 | 34.43 |
11:43 ET | 19497 | 34.51 |
11:45 ET | 15025 | 34.625 |
11:48 ET | 39093 | 34.6281 |
11:50 ET | 31500 | 34.49 |
11:52 ET | 19179 | 34.68 |
11:54 ET | 34162 | 34.705 |
11:56 ET | 13107 | 34.85 |
11:57 ET | 54328 | 34.98 |
11:59 ET | 33018 | 35.17 |
12:01 ET | 27139 | 35.2 |
12:03 ET | 27209 | 35.38 |
12:06 ET | 8267 | 35.16 |
12:08 ET | 28639 | 35.08 |
12:10 ET | 14571 | 35.34 |
12:12 ET | 40097 | 35.5 |
12:14 ET | 44427 | 35.55 |
12:15 ET | 28068 | 35.65 |
12:17 ET | 32607 | 35.6704 |
12:19 ET | 20227 | 35.695 |
12:21 ET | 7865 | 35.8 |
12:24 ET | 42287 | 35.765 |
12:26 ET | 26711 | 35.7485 |
12:28 ET | 15256 | 35.8299 |
12:30 ET | 21682 | 35.79 |
12:32 ET | 14907 | 35.775 |
12:33 ET | 34086 | 35.84 |
12:35 ET | 30026 | 35.3801 |
12:37 ET | 18153 | 35.52 |
12:39 ET | 21367 | 35.69 |
12:42 ET | 6864 | 35.69 |
12:44 ET | 29456 | 35.8129 |
12:46 ET | 54719 | 36.08 |
12:48 ET | 27712 | 36.03 |
12:50 ET | 8387 | 36.015 |
12:51 ET | 6858 | 36.07 |
12:53 ET | 30629 | 36.2 |
12:55 ET | 20216 | 36.4 |
12:57 ET | 36517 | 35.89 |
01:00 ET | 51141 | 35.44 |
01:02 ET | 38337 | 35.23 |
01:04 ET | 32136 | 35.48 |
01:06 ET | 32989 | 35.65 |
01:08 ET | 42543 | 35.56 |
01:09 ET | 39086 | 35.38 |
01:11 ET | 14193 | 35.19 |
01:13 ET | 49507 | 35.2 |
01:15 ET | 41719 | 34.91 |
01:18 ET | 42158 | 34.85 |
01:20 ET | 33268 | 35.005 |
01:22 ET | 9958 | 35.05 |
01:24 ET | 13276 | 35 |
01:26 ET | 22873 | 35.1666 |
01:27 ET | 9776 | 35.01 |
01:29 ET | 10086 | 34.955 |
01:31 ET | 21475 | 35.115 |
01:33 ET | 13852 | 34.87 |
01:36 ET | 20465 | 34.96 |
01:38 ET | 7790 | 35.005 |
01:40 ET | 7027 | 34.965 |
01:42 ET | 9666 | 34.9654 |
01:44 ET | 38241 | 34.85 |
01:45 ET | 1816 | 34.865 |
01:47 ET | 28719 | 34.5 |
01:49 ET | 31720 | 34.54 |
01:51 ET | 10018 | 34.535 |
01:54 ET | 16024 | 34.4 |
01:56 ET | 101251 | 33.96 |
01:58 ET | 27156 | 34.15 |
02:00 ET | 20021 | 34.26 |
02:02 ET | 12847 | 34.2 |
02:03 ET | 40160 | 34.46 |
02:05 ET | 10355 | 34.48 |
02:07 ET | 4179 | 34.65 |
02:09 ET | 19912 | 34.5025 |
02:12 ET | 14097 | 34.75 |
02:14 ET | 3748 | 34.685 |
02:16 ET | 12744 | 34.71 |
02:18 ET | 837 | 34.73 |
02:20 ET | 32939 | 34.91 |
02:21 ET | 8193 | 34.9305 |
02:23 ET | 7250 | 35.005 |
02:25 ET | 1024 | 35.02 |
02:27 ET | 9776 | 35.15 |
02:30 ET | 28767 | 35.255 |
02:32 ET | 19949 | 35.275 |
02:34 ET | 9458 | 35.42 |
02:36 ET | 9532 | 35.35 |
02:38 ET | 7254 | 35.4 |
02:39 ET | 9227 | 35.32 |
02:41 ET | 9283 | 35.3 |
02:43 ET | 3361 | 35.2275 |
02:45 ET | 38850 | 35.17 |
02:48 ET | 8369 | 34.98 |
02:50 ET | 14643 | 34.875 |
02:52 ET | 6393 | 34.965 |
02:54 ET | 7612 | 35.055 |
02:56 ET | 12511 | 34.98 |
02:57 ET | 3047 | 34.975 |
02:59 ET | 14516 | 34.83 |
03:01 ET | 4603 | 34.87 |
03:03 ET | 7290 | 34.95 |
03:06 ET | 3033 | 34.825 |
03:08 ET | 4752 | 34.975 |
03:10 ET | 10166 | 35.175 |
03:12 ET | 8346 | 35.2 |
03:14 ET | 23364 | 35.08 |
03:15 ET | 3057 | 34.9 |
03:17 ET | 12049 | 34.825 |
03:19 ET | 8568 | 34.97 |
03:21 ET | 10753 | 34.94 |
03:24 ET | 3790 | 34.94 |
03:26 ET | 10834 | 34.915 |
03:28 ET | 7769 | 34.905 |
03:30 ET | 6420 | 34.9 |
03:32 ET | 7313 | 34.83 |
03:33 ET | 8638 | 34.795 |
03:35 ET | 11329 | 34.7899 |
03:37 ET | 4402 | 34.82 |
03:39 ET | 8323 | 34.74 |
03:42 ET | 8642 | 34.82 |
03:44 ET | 16280 | 34.7885 |
03:46 ET | 9343 | 34.755 |
03:48 ET | 10062 | 34.635 |
03:50 ET | 13582 | 34.52 |
03:51 ET | 25379 | 34.55 |
03:53 ET | 16997 | 34.715 |
03:55 ET | 41663 | 34.759 |
03:57 ET | 39476 | 34.74 |
04:00 ET | 562625 | 34.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 4.8B | -323.9x | --- |
ADMA Biologics Inc | 5.1B | 77.1x | --- |
Axsome Therapeutics Inc | 4.5B | -15.0x | --- |
Arcellx Inc | 4.7B | -121.2x | --- |
Blueprint Medicines Corp | 6.0B | -45.8x | --- |
Krystal Biotech Inc | 5.1B | 103.1x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.8B |
---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 155.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.20 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -323.9x |
Price/Sales (TTM) | 18.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.